Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic
  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Week in Review: RemeGen Out-Licenses Rights for HER2 ADC to Seagen in $2.6 Billion Deal

Deals and Financings   Yantai's RemeGen out-licensed global rights (ex-Asia) for its novel HER2-targeted ADC to Seagen in a $2.6 billion deal; XtalPi, a US-China AI-based drug discovery company, completed a $400 million Series D financing at an estimated valuation of $2 billion; Shanghai 's HutchMed announced a $310 million deal to acquire greater China rights to Epizyme's epigenetic treatment for niche cancers;   COVID-19 Pandemic   Sorrento Therapeutics of San Diego and Suzhou signed a binding term sheet to license Dyadic's C1-cell protein platform including a COVID-19 vaccine; Advaccine Biopharma Suzhou will conduct China trials of Sinovac's approved COVID-19 vaccine combined with Innovio's DNA COVID-19 vaccine candidate; Trials and Approvals Suzhou Innovent Bio reported its PCSK-9 inhibitor mAb met its primary endpoint in a Phase III trial in  China  patients with genetic hypercholesterolemia; PhaseBio Pharma) and SFJ Pharma announced their partnered drug, a reversal agent for antiplatelets, was approved to start a China Phase III trial; Hangzhou Lynk Pharma started a US Phase I trial of its novel triple-kinase inhibitor in patients with myelofibrosis; Shanghai Belief Biomed was approved to start  China  trials of its IV infusion gene therapy for Hemophilia B; Junshi Biosciences of Shanghai and its  US  partner Coherus Bio reported their PD-1 candidate was granted Breakthrough Therapy Status in the  US .  Stock Symbols: (HK: 9995) (NSDQ: SGEN) (NSDQ/AIM: HCM; HKEX: 13) (NSDQ: SRNE) (NSDQ: INO) (HK: 01801) (NSDQ: PHAS) (HK: 1877; SHA: 688180) (NSDQ: CHRS) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.